Atherosclerosis Halted in Type 2 Diabetes by Pioglitazone for Glycemic Control
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: Late Breaking Trials I, Monday 13th November
THEODORE MAZZONE, University of Illinois, Chicago
The choice of drug for achieving glycemic control in type 2 diabetes has been shown to influence cardiovascular risk as measured by carotid intima thickening. In a study reported to the AHA conference Theodore Mazzone presented results comparing pioglitazone with glimepiride. After his talk in Chicago he discussed his findings with Peter Goodwin.
Pioglitazone and Cardio Risks; Cox-2 Inhibitor Safety
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: Lancet Online 13th November, 2006, Late Breaking Clinical Trials I: Monday 13th November
TIMOTHY GARDNER, Christiana Care, Delaware
Timothy Gardner, Program Chair of the American Heart Association Sessions commented on the presentations of Theodore Mazzone and Chris Cannon.
Cox-2 Inhibitor Etoricoxib: No More Risk than Non-Steroidal
American Heart Association Scientific Sessions 2006 November 12-15th Chicago, Illinois. Abstract: LB I
CHRISTOPHER CANNON, Brigham And Women’s Hospital, Boston
One of the Cox-2 inhibitor family of drugs for arthritis – etoricoxib – may have proved itself to affect cardiovascular risks no more than the non-steroidal anti-inflammatory drug, diclofenac. This was announced at the AHA Sessions in Chicago and has been simultaneously published in the Lancet. Christopher Cannon told Sarah Maxwell about his group’s findings in the MEDAL study.